Eam Investors, LLC Fate Therapeutics Inc Transaction History

Eam Investors, LLC

  • $581 Million
  • Q3 2024

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 11, 2021
SELL
$72.16 - $117.4 $1.67 Million - $2.72 Million
-23,209 Closed
0 $0
Q4 2020

Feb 11, 2021
SELL
$38.09 - $100.95 $493,303 - $1.31 Million
-12,951 Reduced 35.82%
23,209 $2.11 Million
Q3 2020

Nov 13, 2020
SELL
$30.41 - $40.5 $424,219 - $564,975
-13,950 Reduced 27.84%
36,160 $1.45 Million
Q2 2020

Aug 13, 2020
SELL
$20.21 - $35.23 $354,422 - $617,828
-17,537 Reduced 25.92%
50,110 $1.72 Million
Q1 2020

May 13, 2020
BUY
$17.28 - $31.88 $1.17 Million - $2.16 Million
67,647 New
67,647 $1.5 Million
Q4 2019

Feb 11, 2020
SELL
$13.39 - $20.73 $516,050 - $798,934
-38,540 Closed
0 $0
Q3 2019

Nov 13, 2019
SELL
$15.47 - $22.5 $499,046 - $725,827
-32,259 Reduced 45.56%
38,540 $599,000
Q1 2019

May 13, 2019
SELL
$13.15 - $18.71 $117,258 - $166,837
-8,917 Reduced 11.19%
70,799 $1.24 Million
Q4 2018

Feb 13, 2019
SELL
$11.48 - $16.98 $23,269 - $34,418
-2,027 Reduced 2.48%
79,716 $1.02 Million
Q3 2018

Nov 08, 2018
BUY
$8.75 - $16.29 $175,542 - $326,809
20,062 Added 32.53%
81,743 $1.33 Million
Q2 2018

Aug 03, 2018
SELL
$9.16 - $13.48 $1.99 Million - $2.93 Million
-217,480 Reduced 77.9%
61,681 $699,000
Q1 2018

May 14, 2018
BUY
$6.3 - $13.77 $1.76 Million - $3.84 Million
279,161 New
279,161 $2.73 Million

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $235M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Eam Investors, LLC Portfolio

Follow Eam Investors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eam Investors, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email